Abiraterone acetate
![Active Ingredient Dosage Strength and Form Comparator Drug1 Marketing Authorization Holder [Manufacturer] Registration Number A](http://data.docslib.org/img/264x/2ea05633623afd77e0e8c61c93c312a1.webp)
Top View
- Pharmacokinetics of Abiraterone Acetate Released from a Tablet Based on Lipid Matrix in Beagle Dogs
- Combined Index to USP 41 and NF 36, Volumes 1–5
- Zytiga, INN-Abiraterone Acetate
- Your 2021 Premium Value Formulary Effective July 1, 2021
- Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-Resistant Prostate Cancer
- DCS Pharma Portfolio
- Drug Formulary List
- Drugs Contraindicated in Pregnancy
- Prsandoz® ABIRATERONE
- ZYTIGA® (Abiraterone Acetate) Tablets 1 HIGHLIGHTS OF
- Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate In
- (CHMP) Agenda for the Meeting on 21-24 June 2021
- Safety and Effectiveness of Neoadjuvant Luteinizing Hormone
- ZYTIGA with Caution in Patients with a ZYTIGA Safely and Effectively
- Appendix a - Product Name Index
- To USP 39–NF 34, First Supplement the Following Index Is For
- Download API Catalog
- Australian Public Assessment Report for Abiraterone Acetate